Research
Hormonal
Ramipril is associated with lower rates of new diagnosis of diabetes in high-risk individuals, with 3.6% in the ramipril group developing diabetes compared to 5.4% in the placebo group (RR, 0.66; P<.001).
Practitioners may consider ramipril as a preventive strategy for diabetes in high-risk patients.
StrongSupportsmedium confidence
One hundred and two individuals (3.6%) in the ramipril group developed diabetes compared with 155 (5.4%) in the placebo group (relative risk [RR], 0.66; 95% confidence interval [CI], 0.51-0.85, P<.001).
Why this rating
Based on a large randomized controlled trial design.
Source
Ramipril and the Development of Diabetes
Salim Yusuf · JAMA · 2001
DOI 10.1001/jama.286.15.1882
rct · n=5720Cited 546×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →